Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT. (28th February 2020)

• Record Type: Journal Article
• Authors: McLornan, Donal P.; Malpassuti, Vittoria; Lippinkhof‐Kozijn, Anne; Potter, Victoria; Beelen, Dietrich; Bunjes, Donald; Sengeloev, Henrik; Radujkovic, Aleksandar; Passweg, Jakob; Chalandon, Yves; Kröger, Nicolaus; Wulf, Gerald G.; Johansson, Jan‐Erik; Ciceri, Fabio; Bornhäuser, Martin; Holler, Ernst; Guffroy, Blandine; Martin, Sonja; Neubauer, Andreas; Gramatski, Martin; Robin, Marie; Iacobelli, Simona; Hayden, Patrick; Hernández Boluda, Juan C.; Czerw, Tomasz; Yakoub‐Agha, Ibrahim
• Is Part Of: British journal of haematology. Volume 190:Number 3(2020)
• Page Start: 437
• Page End: 441
• Publication Date: 2020-02-28
• Subjects: allogeneic stem cell transplant -- conditioning -- myeloproliferative neoplasms unclassifiable -- non‐relapse mortality; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.16537
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Myeloproliferative Neoplasm (MPN), unclassifiable (MPN‐U) is a heterogeneous disease with regards to both clinical phenotype and disease course. Patients may initially be asymptomatic or present with leucocytosis or thrombocytosis, anaemia, progressive splenomegaly, constitutional symptom, thromboses or accelerated/blastic phase disease. Treatment strategies are variable and there are no widely accepted consensus management guidelines for MNU‐U. Allogeneic Haematopoietic Cell Transplantation (allo‐HCT) remains the only curative strategy yet outcomes, to date, are not well defined. We hereby report on the largest retrospective study of patients with MPN‐U undergoing allo‐HCT, highlighting the potentially curative role and providing clinicians with robust engraftment, GvHD and outcome data to facilitate patient discussion.